171 related articles for article (PubMed ID: 31374137)
1. Immunomorphology and molecular biology of mixed primary liver cancers: is Nestin a marker of intermediate-cell carcinoma?
Malvi D; de Biase D; Fittipaldi S; Grillini M; Visani M; Pession A; D'Errico A; Vasuri F
Histopathology; 2020 Jan; 76(2):265-274. PubMed ID: 31374137
[TBL] [Abstract][Full Text] [Related]
2. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
3. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing.
Jeon J; Maeng LS; Bae YJ; Lee EJ; Yoon YC; Yoon N
Cancer Genomics Proteomics; 2018; 15(4):291-298. PubMed ID: 29976634
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
[TBL] [Abstract][Full Text] [Related]
6. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308
[TBL] [Abstract][Full Text] [Related]
7. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
[TBL] [Abstract][Full Text] [Related]
8. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.
Wang Y; Yang Q; Li S; Luo R; Mao S; Shen J
Clin Radiol; 2019 May; 74(5):407.e1-407.e10. PubMed ID: 30799097
[TBL] [Abstract][Full Text] [Related]
9. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
10. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
[TBL] [Abstract][Full Text] [Related]
11. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
12. Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.
Na HY; Kim JH; Kim H; Cho JY; Han HS; Jang ES; Kim JW; Jeong SH; Heo J; Kim JW; Kim JW; Ahn S
Histopathology; 2024 Jan; 84(2):402-408. PubMed ID: 37903726
[TBL] [Abstract][Full Text] [Related]
13. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.
Xue R; Chen L; Zhang C; Fujita M; Li R; Yan SM; Ong CK; Liao X; Gao Q; Sasagawa S; Li Y; Wang J; Guo H; Huang QT; Zhong Q; Tan J; Qi L; Gong W; Hong Z; Li M; Zhao J; Peng T; Lu Y; Lim KHT; Boot A; Ono A; Chayama K; Zhang Z; Rozen SG; Teh BT; Wang XW; Nakagawa H; Zeng MS; Bai F; Zhang N
Cancer Cell; 2019 Jun; 35(6):932-947.e8. PubMed ID: 31130341
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma.
Cirqueira CS; Felipe-Silva AS; Wakamatsu A; Marins LV; Rocha EC; de Mello ES; Alves VAF
Pathol Oncol Res; 2019 Oct; 25(4):1363-1371. PubMed ID: 29464551
[TBL] [Abstract][Full Text] [Related]
15. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.
Yano Y; Yamamoto J; Kosuge T; Sakamoto Y; Yamasaki S; Shimada K; Ojima H; Sakamoto M; Takayama T; Makuuchi M
Jpn J Clin Oncol; 2003 Jun; 33(6):283-7. PubMed ID: 12913082
[TBL] [Abstract][Full Text] [Related]
16. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography.
Li R; Yang D; Tang CL; Cai P; Ma KS; Ding SY; Zhang XH; Guo DY; Yan XC
BMC Cancer; 2016 Feb; 16():158. PubMed ID: 26917546
[TBL] [Abstract][Full Text] [Related]
17. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
[TBL] [Abstract][Full Text] [Related]
18. The expression of arginase-1, keratin (K) 8 and K18 in combined hepatocellular-cholangiocarcinoma, subtypes with stem-cell features, intermediate-cell type.
Akiba J; Nakashima O; Hattori S; Naito Y; Kusano H; Kondo R; Nakayama M; Tanikawa K; Todoroki K; Umeno Y; Nakamura K; Sanada S; Yamaguchi R; Ogasawara S; Yano H
J Clin Pathol; 2016 Oct; 69(10):846-51. PubMed ID: 26969740
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
[TBL] [Abstract][Full Text] [Related]
20. Spalt-like transcription factor 4 immunopositivity is associated with epithelial cell adhesion molecule expression in combined hepatocellular carcinoma and cholangiocarcinoma.
Tanaka Y; Aishima S; Kohashi K; Okumura Y; Wang H; Hida T; Kotoh K; Shirabe K; Maehara Y; Takayanagi R; Oda Y
Histopathology; 2016 Apr; 68(5):693-701. PubMed ID: 26267070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
